2018
DOI: 10.1007/s00404-018-4922-2
|View full text |Cite
|
Sign up to set email alerts
|

Sexual activity and quality of life in patients after treatment for breast and ovarian cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

6
35
2
4

Year Published

2019
2019
2023
2023

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 33 publications
(51 citation statements)
references
References 31 publications
6
35
2
4
Order By: Relevance
“…They found that sexual activity was associated with a better QOL (p = 0.004). Our data corroborate these previous findings that the best QOL culminates in better sexual function [35].…”
Section: Discussionsupporting
confidence: 92%
“…They found that sexual activity was associated with a better QOL (p = 0.004). Our data corroborate these previous findings that the best QOL culminates in better sexual function [35].…”
Section: Discussionsupporting
confidence: 92%
“…In contrast, in a retrospective study, an average of 24 months after completion of therapy, sexually active ovarian cancer survivors showed no significant difference in sexual function and quality of life compared to healthy non-cancer survivor controls [44]. In another cross-sectional study of ovarian cancer survivors who had completed treatment and were in remission for an average of 56.9 months versus healthy controls, there was no difference in sexual satisfaction exception for vaginal dryness which was greater in those who had undergone cancer treatment [45].…”
Section: Sexual Dysfunctionmentioning
confidence: 70%
“…A recent retrospective study showed that breast cancer patients are more affected than patients with ovarian cancer or healthy controls: decreased or no interest in sexual activity was frequently reported with a significant association to less satisfaction and more discomfort (dyspareunia); however, the lack of desire was not associated with global health status, QoL or the ability to experience orgasms; estrogen deprivation (gonadotropin-releasing hormone agonists, AIs) seemed to have more impact than tamoxifen. 124 Dyspareunia is often caused by vaginal dryness. The first choice for treating vaginal dryness and soreness are hormone-free lubricants (e.g.…”
Section: Iv/b 86%mentioning
confidence: 99%